CLRB Cellectar Biosciences, Inc.
USHealthcareAs of 2026-07-09 14:10
Why CLRB matters now
Cellectar Biosciences, Inc. (CLRB) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.71 with +1.12% on the session and $8.7M in market capitalization; recent performance reads 1-month -8.82% and YTD -5.42%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.7M, and EPS of $-1.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -208.7%.
The latest indexable market news headline is "Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.00; recent insider activity includes Gu Andrew filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.51
P/S
0.00
EV/EBITDA
-0.10
DCF Value
$4.38
FCF Yield
-208.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-264.8%
ROA
-187.4%
ROIC
-358.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.7M | $-1.33 |
| Q4 2025 | $0.00 | $-5.3M | $-1.25 |
| FY 2025 | $0.00 | $-21.8M | $-8.35 |
| Q3 2025 | $0.00 | $-4.4M | $-1.41 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$11.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.54
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.